PCM
AUPH icon

Penserra Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Penserra Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,945
Closed -$65K – 1378
2021
Q3 		$65K Buy
2,945
+30
+1% +$476 ﹤0.01% 969
2021
Q2 		$37K Buy
2,915
+30
+1% +$382 ﹤0.01% 1064
2021
Q1 		$37K Sell
2,885
-55
-2% -$798 ﹤0.01% 866
2020
Q4 		$40K Buy
2,940
+1,860
+172% +$27.1K ﹤0.01% 724
2020
Q3 		$15K Buy
+1,080
New +$15.6K ﹤0.01% 770

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.05B AUM 111.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Penserra Capital Management's AUPH Position: Q4 2021 in Review

Penserra Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 2,945 shares — an estimated $65K sold.

Penserra Capital Management first reported a position in AUPH in Q3 2020 and held it in 5 quarters. The position peaked at $65K in Q3 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

  • Penserra Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,945 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $65K.
  • Penserra Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Aurinia Pharmaceuticals position peaked at $65K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.